SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Period Ended September 30, 2002.
or
o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period From to .
Commission file number 0-27436
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
94-3171940 |
|
(State or Other Jurisdiction of |
|
(I.R.S. Employer |
|
Incorporation or Organization) |
|
Identification No.) |
400 Oyster Point Blvd., Suite 505, South San Francisco, California 94080
(Address of Principal Executive Offices including zip code)
(650) 244-4990
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o
There were 27,642,085 shares of the Registrant’s Common Stock issued and outstanding on November 6, 2002.
Titan Pharmaceuticals, Inc.
Index to Form 10-Q
TITAN PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
|
|
|
September 30, |
|
December 31, |
|
||
|
|
|
2002 |
|
2001 |
|
||
|
|
|
(unaudited) |
|
(Note A) |
|
||
|
Assets |
|
|
|
|
|
||
|
Current assets |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
7,037 |
|
$ |
5,772 |
|
|
Marketable securities |
|
74,412 |
|
99,279 |
|
||
|
Prepaid expenses, receivables, and other current assets |
|
1,294 |
|
906 |
|
||
|
Total current assets |
|
82,743 |
|
105,957 |
|
||
|
Furniture and equipment, net |
|
996 |
|
575 |
|
||
|
Investment in other companies |
|
300 |
|
600 |
|
||
|
|
|
$ |
84,039 |
|
$ |
107,132 |
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
||
|
Current liabilities |
|
|
|
|
|
||
|
Accounts payable |
|
$ |
1,175 |
|
$ |
894 |
|
|
Accrued clinical trials expenses |
|
1,337 |
|
2,156 |
|
||
|
Other accrued liabilities |
|
906 |
|
714 |
|
||
|
Deferred contract revenue |
|
¾ |
|
2,000 |
|
||
|
Total current liabilities |
|
3,418 |
|
5,764 |
|
||
|
Minority interest - Series B preferred stock of Ingenex, Inc. |
|
1,241 |
|
1,241 |
|
||
|
Stockholders' equity |
|
|
|
|
|
||
|
Common stock, at amounts paid in |
|
191,685 |
|
191,684 |
|
||
|
Additional paid-in capital |
|
9,157 |
|
9,017 |
|
||
|
Deferred compensation |
|
(689 |
) |
(795 |
) |
||
|
Accumulated deficit |
|
(120,948 |
) |
(101,670 |
) |
||
|
Accumulated other comprehensive income |
|
175 |
|
1,891 |
|
||
|
Total stockholders' equity |
|
79,380 |
|
100,127 |
|
||
|
|
|
$ |
84,039 |
|
$ |
107,132 |
|
Note A: The balance sheet has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the United States for complete financial statement presentation.
See Notes to Condensed Consolidated Financial Statements
2
TITAN PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amount)
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
||||||||
|
|
|
2002 |
|
2001 |
|
2002 |
|
2001 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Contract and grant revenue |
|
$ |
158 |
|
$ |
530 |
|
$ |
2,656 |
|
$ |
1,483 |
|
|
License revenue |
|
¾ |
|
¾ |
|
¾ |
|
2,500 |
|
||||
|
Total revenue |
|
158 |
|
530 |
|
2,656 |
|
3,983 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||
|
Research and development |
|
7,202 |
|
5,756 |
|
21,607 |
|
16,096 |
|
||||
|
General and administrative |
|
1,314 |
|
1,312 |
|
3,915 |
|
4,107 |
|
||||
|
Total operating expenses |
|
8,516 |
|
7,068 |
|
25,522 |
|
20,203 |
|
||||
|
Loss from operations |
|
(8,358 |
) |
(6,538 |
) |
(22,866 |
) |
(16,220 |
) |
||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
||||
|
Interest income, net |
|
1,070 |
|
1,770 |
|
3,924 |
|
5,172 |
|
||||
|
Other expense |
|
(8 |
) |
(19 |
) |
(336 |
) |
(92 |
) |
||||
|
Other income, net |
|
1,062 |
|
1,751 |
|
3,588 |
|
5,080 |
|
||||
|
Net loss |
|
$ |
(7,296 |
) |
$ |
(4,787 |
) |
$ |
(19,278 |
) |
$ |
(11,140 |
) |
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic and diluted net loss per share |
|
$ |
(0.26 |
) |
$ |
(0.17 |
) |
$ |
(0.70 |
) |
$ |
(0.40 |
) |
|
|
|
|
|
|
|
|
|
|
|
||||
|
Weighted average shares used in computing basic and diluted net loss per share |
|
27,642 |
|
27,643 |
|
27,642 |
|
27,577 |
|
||||
|
|
|||||||||||||
See Notes to Condenses Consolidated Financial Statements
3
TITAN PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
|
|
|
Nine Months Ended September 30, |
|
||||
|
|
|
2002 |
|
2001 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
||
|
Net loss |
|
$ |
(19,278 |
) |
$ |
(11,140 |
) |
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
|
||
|
Depreciation and amortization |
|
912 |
|
413 |
|
||
|
Non-cash compensation related to stock options |
|
245 |
|
498 |
|
||
|
Changes in operating assets and liabilities: |
|
|
|
|
|
||
|
Prepaid expenses, receivables and other assets |
|
(729 |
) |
(865 |
) |
||
|
Accounts payable and other accrued liabilities |
|
(346 |
) |
57 |
|
||
|
Deferred contract revenue |
|
(2,000 |
) |
¾ |
|
||
|
Net cash used in operating activities |
|
(21,196 |
) |
(11,037 |
) |
||
|
|
|
|
|
|
|
||
|
Cash flows from investing activities: |
|
|
|
|
|
||
|
Purchases of furniture and equipment, net |
|
(692 |
) |
(204 |
) |
||
|
Purchases of marketable securities |
|
(14,922 |
) |
(61,299 |
) |
||
|
Proceeds from maturities of marketable securities |
|
29,543 |
|
41,495 |
|
||
|
Proceeds from sales of marketable securities |
|
8,531 |
|
16,127 |
|
||
|
Net cash provided by (used in) investing activities |
|
22,460 |
|
(3,881 |
) |
||
|
|
|
|
|
|
|
||
|
Cash flows from financing activities: |
|
|
|
|
|
||
|
Issuance of common stock, net |
|
1 |
|
850 |
|
||
|
Net cash provided by financing activities |
|
1 |
|
850 |
|
||
|
|
|
|
|
|
|
||
|
Net increase (decrease) in cash and cash equivalents |
|
1,265 |
|
(14,068 |
) |
||
|
Cash and cash equivalents at beginning of period |
|
5,772 |
|
20,300 |
|
||
|
Cash and cash equivalents at end of period |
|
7,037 |
|
6,232 |
|
||
|
Marketable securities at end of period |
|
74,412 |
|
102,681 |
|
||
|
Cash, cash equivalents and marketable securities at end of period |
|
$ |
81,449 |
|
$ |
108,913 |
|
4
TITAN PHARMACEUTICALS, INC.
(unaudited)
1. Organization and Summary of Significant Accounting Policies
The Company
We are a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. We operate in one business segment, the development of biopharmaceutical products.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements include the accounts of Titan and its subsidiaries after elimination of all significant intercompany accounts and transactions. Certain prior year balances have been reclassified to conform to the current year presentation. These financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for a complete financial statements presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September 30, 2002 are not necessarily indicative of the results that may be expected for the year ending December 31, 2002.
These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. annual report on Form 10-K for the year ended December 31, 2001.
Revenue Recognition
Contract revenue for research and development is recorded as earned based on the performance requirements of the contract. Revenue associated with performance milestones, considered “at-risk” until the milestones are completed, is recognized based on the achievement of the milestones as defined in the respective agreements. Government grants, which support our research effort in specific projects, generally provide for reimbursement of approved costs as defined in the grant documents, and revenue is recognized when associated project costs are incurred.
Operating Subsidiaries
We conduct a small portion of our operations through two subsidiaries: Ingenex, Inc. and ProNeura, Inc. At September 30, 2002, we owned 81% of Ingenex (assuming the conversion of all preferred stock to common stock) and 79% of ProNeura.
2. Net Loss Per Share
We calculate net loss per share using the weighted average common shares outstanding for the period. For periods ended September 30, 2002 and 2001, the effect of an additional 6,387,714 and 4,662,448 shares,
5
respectively, related to our authorized and issued convertible preferred stock and options, were not included in the computation of diluted earnings per share because they are anti-dilutive.
3. Comprehensive Income
Comprehensive income is comprised of net loss and other comprehensive income. The only component of other comprehensive income is unrealized gains and losses from our marketable securities. Comprehensive loss for the three and nine months ended September 30, 2002 were $7.6 million and $21.0 million, respectively, and for the three and nine months ended September 30, 2001 were $3.9 million and $9.4 million, respectively.
4. Related Parties Transactions
In February 2001, we made a loan to a vice president officer in the principal amount of $373,000 bearing interest at prime rate. The loan was due and payable on August 7, 2002. As of November 14, 2002, the remaining principal balance is $53,000 and it is expected that the remaining balance will be repaid by year end 2002.
5. Spheramine milestone payment from Schering AG
In February 2002, we announced that we received a $2.0 million milestone payment from Schering, Titan’s corporate partner for worldwide development, manufacture and commercialization of SpheramineÒ, Titan’s novel cell therapy for the treatment of Parkinson’s disease. The milestone payment followed Schering’s decision in the first quarter 2002 to initiate larger, randomized clinical testing of Spheramine for the treatment of patients with late-stage Parkinson’s disease following the successful completion of Titan’s Phase I/II clinical study of Spheramine. As a result, Titan recognized $2.0 million in contract revenue in the first quarter.
6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion contains certain forward-looking statements, within the meaning of the “safe harbor” provisions of the Private Securities Reform Act of 1995, the attainment of which involves various risks and uncertainties. Forward-looking statements may be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “believe,” “estimate,” “plan,” “anticipate,” “continue,” or similar terms, variations of those terms or the negative of those terms. Our actual results may differ materially from those described in these forward-looking statements due to, among other factors, the results of ongoing research and development activities and pre-clinical testing, the results of clinical trials and the availability of additional financing through corporate partnering arrangements or otherwise. Additional factors include our ability to protect our patents and proprietary rights, ability to comply with extensive government regulations, and other factors and risks detailed under the caption “Risk Factors” in the Company’s 2001 Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Stockholders and prospective investors in the Company should carefully consider these risk factors. The Company disclaims any obligation to update these statements for subsequent events.
Spheramine®, CeaVac®, TriAb®, TriGem™, Pivanex®, CCM™, Probuphine™, Apromax™, and Promafen™ are trademarks of Titan Pharmaceuticals, Inc.
Overview
We are a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. Our product development programs focus on large pharmaceutical markets with significant unmet medical needs.
We currently have 12 products in development, seven of which are in clinical development, with two products in expanded human trials for safety and efficacy, known as Phase III clinical trials. We have five products in earlier stage trials for dosing, and preliminary safety and efficacy, known as Phase I and Phase II clinical trials. In addition to these programs, we have three products in pre-clinical development.
We are independently developing our product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG (Novartis) and Schering AG (Schering), as well as collaborations with several government-sponsored clinical cooperative groups. These collaborations help fund product development and enable us to retain significant economic interest in our products.
The results of a study evaluating the potential effect of iloperidone, an antipsychotic medication in development, on the EKG profile of patients receiving the drug were announced in July 2002. The study indicated that results for iloperidone were roughly comparable to that for ziprasidone, one of the approved agents in the study. The potential of these data to support any possible regulatory submission for iloperidone is not currently known. In addition, this may potentially limit the opportunity of iloperidone as first line therapy for schizophrenia. Novartis and Titan are currently preparing to evaluate next steps for the iloperidone program.
The following table provides a summary status of our products in development:
|
Product |
|
Potential Indication(s) |
|
Phase of Development |
|
Marketing Rights |
|
|
Iloperidone |
|
Schizophrenia, psychosis |
|
Phase III |
|
Novartis Pharma AG |
|
|
Spheramine |
|
Parkinson’s Disease |
|
Phase II (to be initiated Q4 2002) |
|
Schering AG |
|
|
Probuphine |
|
Opiate addiction |
|
Phase I (to be initiated Q1 2003) |
|
Titan |
|
|
Promafen |
|
Alcoholism |
|
Pre-clinical |
|
Titan |
|
|
Apromax |
|
Parkinson’s Disease |
|
Pre-clinical |
|
Titan |
|
7
|
Product |
|
Potential Indication(s) |
|
Phase of Development |
|
Marketing Rights |
|
CeaVac |
|
Colorectal, gastrointestinal and pancreatic cancer |
|
Phase III (colorectal cancer) |
|
Titan |
|
TriAb |
|
Breast and ovarian cancer |
|
Phase II (breast cancer) |
|
Titan |
|
CeaVac & TriAb |
|
Metastatic breast, non-small cell lung, and colorectal cancer |
|
Phase II (colorectal cancer, non-small cell lung cancer) |
|
Titan |
|
TriGem & TriAb |
|
Small cell lung cancer |
|
Phase II (to be initiated Q4 2002) |
|
Titan |
|
Pivanex |
|
Non-small cell lung cancer |
|
Phase II |
|
Titan |
|
Gallium Maltolate |
|
Myeloma, prostate and bladder cancer, lymphoma |
|
Phase I/II |
|
Titan |
|
RB94 |
|
Head, neck, and pancreatic cancer |
|
Pre-clinical |
|
Titan |
Our products are at various stages of development and may not be successfully developed or commercialized. We do not currently have any products being commercially sold. Our proposed products will require significant further capital expenditures, development, testing, and regulatory clearances prior to commercialization. We may experience unanticipated problems relating to product development and cannot predict whether we will successfully develop and commercialize any products. An estimation of product completion dates and completion costs can vary significantly for each product and are difficult to predict. Various statutes and regulations also influence our product development progress and the success of obtaining approval is highly uncertain. For a full discussion of risks and uncertainties in our product development, see “Risk Factors — Our products are at various stages of development and may not be successfully developed or commercialized” in our 2001 annual report on Form 10-K.
Results of Operations
Revenues for the third quarter of 2002 were $158,000, compared to $0.5 million for the same quarter in 2001. For the first nine months of 2002, revenues were $2.7 million, compared to $4.0 million for the same nine-month period in 2001. The higher revenue in 2001 was a result of higher one-time license fee payments to Titan from corporate partners, higher contract revenue and SBIR grant payments for a program which was completed in Q1 2002.
Research and development expenses for the third quarter of 2002 were $7.2 million, compared to $5.8 million for the same quarter in 2001. For the first nine months of 2002, research and development expenses were $21.6 million, compared to $16.1 million for the same nine-month period in 2001. The increase resulted primarily from our expanded clinical and pre-clinical operations, including planned increases in expenditures associated with our ongoing randomized, placebo-controlled Phase III clinical study of CeaVac in Dukes D colorectal cancer, our study of gallium maltolate in several different cancers, as well as other clinical studies of CeaVac and TriAb and progress in our pre-clinical development of drug candidates for the treatment of opiate and alcohol addiction.
8
General and administrative expenses for the third quarter of 2002 were $1.3 million compared to $1.3 million for the same quarter in 2001. For the first nine months of 2002, general and administrative expenses were $3.9 million, compared to $4.1 million for the same nine-month period in 2001. The slight decrease for the nine-month period resulted primarily from the absence of certain administrative costs.
Other income, net, for the third quarter of 2002 was $1.1 million compared to $1.8 million for the same quarter in 2001. For the first nine months of 2002, other income, net of a $300,000 write-down of certain long-term investments, was $3.6 million compared to $5.1 million for the same nine-month period in 2001. The decrease, primarily in interest income, was a result of lower interest rates and decreased cash and marketable securities.
As a result of the foregoing, we had and expected net loss for the third quarter of 2002 of $7.3 million, or $0.26 per share, compared to $4.8 million, or $0.17 per share, for the same quarter in 2001. For the first nine months of 2002, our net loss was $19.3 million, or $0.70 per share, compared to $11.1 million, or $0.40 per share, for the same nine-month period in 2001.
Liquidity and Capital Resources
We have funded our operations since inception through our initial public offering and private placements of our securities, as well as proceeds from warrant and option exercises, corporate licensing and collaborative agreements, and government sponsored research grants. At September 30, 2002, we had $81.4 million of cash, cash equivalents, and marketable securities.
Uses of cash in operating activities were primarily to fund product development programs and administrative expenses. Our operating activities used $21.2 million and $11.0 million of cash in the first nine months in 2002 and 2001, respectively. We have entered into various agreements with research institutions, universities, and other entities for the performance of research and development activities and for the acquisition of licenses related to those activities. The aggregate commitments we have under these agreements, including minimum license payments, for the next 12 months is approximately $0.6 million. Certain of our licenses require us to pay royalties on future product sales, if any. In addition, in order to maintain license and other rights while products are under development, we must comply with customary licensee obligations, including the payment of patent related costs and diligent efforts in product development.
We expect to continue to incur substantial additional operating losses from costs related to continuation and expansion of product and technology development, clinical trials, and administrative activities. We believe that we currently have sufficient working capital to sustain our planned operations through 2005.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our market risk disclosures set forth in our Form 10-K for the period ended December 31, 2001, have not changed significantly.
Item 4. Controls and Procedures
Based on the evaluation by Titan under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Titan’s disclosure controls and procedures pursuant to Rule 13a-14 of the Securities and Exchange Act of 1934, as amended (the Exchange Act), as of a date within 90 days of the filing date of this quarterly report, our Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures are effective in ensuring that information required to be disclosed by Titan in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified by the Securities and Exchange Commission’s rules and forms.
9
Subsequent to the date of their evaluation, there were no significant changes in Titan’s internal controls or in other factors that could significantly affect these controls nor were any corrective actions required with regard to significant deficiencies and material weaknesses.
Item 4. Submission of Matters to a Vote of Security Holders
On August 15, 2002, the Company held its Annual Meeting of Stockholders. Matters voted upon at the meeting and the number of affirmative votes, negative votes, withheld votes and abstentions cast with respect to each such matter were as follows:
|
|
|
|
Affirmative |
|
Withheld |
|
|
|
|
Votes |
|
Votes |
|
1. |
Election of the Company’s Directors: |
|
|
|
|
|
|
Louis R. Bucalo, M.D. |
|
19,539,655 |
|
1,985,907 |
|
|
Ernst-Günter Afting, M.D., Ph.D. |
|
20,516,587 |
|
1,008,975 |
|
|
Victor J. Bauer, Ph.D. |
|
19,532,605 |
|
1,992,957 |
|
|
Eurelio M. Cavalier |
|
20,517,137 |
|
1,008,425 |
|
|
Michael K. Hsu |
|
20,520,287 |
|
1,005,275 |
|
|
Hubert Huckel, M.D. |
|
20,513,641 |
|
1,011,921 |
|
|
M. David MacFarlane, Ph.D. |
|
20,517,287 |
|
1,008,275 |
|
|
Ley S. Smith |
|
20,501,526 |
|
1,024,036 |
|
|
Konrad M. Weis, Ph.D. |
|
20,498,555 |
|
1,027,007 |
|
|
|
Affirmative |
|
Against |
|
|
|
|
|
Votes |
|
Votes |
|
Abstentions |
|
|
|
|
|
|
|
|
|
2. Approval and ratification of the Company’s 2002 Stock Option Plan |
|
8,713,388 |
|
2,285,888 |
|
63,611 |
|
|
|
|
|
|
|
|
|
There were 10,462,675 broker non-votes on this matter. |
|
|
|
|
||
|
|
|
|
|
|
|
|
|
3. Approval of the appointment of Ernst & Young LLP as independent auditors |
|
21,199,882 |
|
295,233 |
|
30,447 |
As a result of the foregoing, each of the nominees was elected director of the Company until the next annual meeting of stockholders or until their successor is elected and qualified, the Company’s 2002 Stock Option Plan was approved and ratified, and the appointment of Ernst & Young LLP as the Company’s independent auditors was approved.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
99.0 Section 906 Certifications
(b) Reports on Form 8-K
We filed a current report on Form 8-K with the Securities Exchange Commission on July 22, 2002 to announce Novartis Pharma AG has completed a study evaluating the potential effect of iloperidone, an antipsychotic medication in development, on the EKG profile of patients receiving the drug.
10
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TITAN PHARMACEUTICALS, INC.
|
November 14, 2002 |
|
By: |
|
/s/ Louis R. Bucalo |
||
|
|
|
|
|
Louis R. Bucalo, M.D. |
||
|
|
|
|
|
Chairman, President and Chief Executive Officer |
||
|
|
|
|
|
|
|
|
|
November 14, 2002 |
|
By: |
|
/s/ Robert E. Farrell |
||
|
|
|
|
|
Robert E. Farrell, J.D. |
||
|
|
|
|
|
Executive Vice President and Chief Financial Officer |
||
11
CERTIFICATION BY CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Louis R. Bucalo, M.D., Chairman, President and Chief Executive Officer of Titan Pharmaceuticals, Inc., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Titan Pharmaceuticals, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and
c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors:
a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and
12
6. The registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
|
Date: November 14, 2002 |
/s/ Louis R. Bucalo |
|
|
Louis R. Bucalo, M.D. |
|
|
Chairman, President and Chief Executive Officer |
13
CERTIFICATION BY CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Robert E. Farrell, J.D., Executive Vice President and Chief Financial Officer of Titan Pharmaceuticals, Inc., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Titan Pharmaceuticals, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and
c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors:
a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and
14
6. The registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
|
Date: November 14, 2002 |
|
/s/ Robert E. Farrell |
|
|
|
Robert E. Farrell, J.D. |
|
|
|
Executive Vice President and Chief Financial Officer |
15